Continuous innovation shapes the Medtronic Evolut™ valve design, prioritizing performance that patients and clinicians can trust.
With its supra-annular, self-expanding valve frame, Evolut™ TAVI is built on the original CoreValve™ platform which has consistently shown strong effective orifice areas (EOAs) and low gradients over time.1–3
How did we design for durability?
By decoupling the native annular plane where the sealing occurs, from the working portion of the prosthetic leaflets, you can facilitate circularity and maximize leaflet coaptation.
Taller leaflet mounting allows for a greater distance between the commissure and the edge of the leaflet, distributing stress over a greater distance.
The tall valve keeps the working portion above and unconstrained by the native annulus (supra-annular), allowing for a large EOA.
External tissue wrap increases surface contact with native anatomy to reduce the risk of paravalvular leak (PVL).4
Large EOAs mean less restriction of blood flow through the valve.5
Large EOAs mean less workload for the ventricle.6
Large EOAs have been correlated to less prosthesis-patient mismatch (PPM).5
Less PPM and low gradients after aortic valve implantation have been linked to:
CoreValve™ and Evolut™ TAVI systems are the only platform to demonstrate a durability benefit over SAVR at five years in intermediate or greater risk patients.†,11
Medtronic TAVI platforms demonstrated significantly lower rates of structural valve deterioration (SVD)‡ versus SAVR at five years.
Discover these TAVI versus SAVR durability data.
Structural valve deterioration out to 5 years
† In pooled analysis of intermediate and high-risk patients. Devices used: CoreValve™ 88.5%/Evolut™ R 11.5%.
‡ Structural valve deterioration (SVD) was defined as an increase in mean gradient ≥ 10 mmHg with a mean gradient ≥ 20 mmHg at last echo OR new onset/increase of central AR of ≥ moderate in severity.
The CoreValve™/Evolut™ platform has demonstrated excellent hemodynamic results compared with balloon-expandable valves and SAVR across clinical trials.
The Confida™ Brecker guidewire is specifically designed for transcatheter aortic valve implantation (TAVI) procedures.
The Evolut™ FX transcatheter aortic valve implantation (TAVI) system sets new expectations for precision, control, and predictability in TAVI procedures.
The Evolut™ FX+ transcatheter aortic valve system is designed with specific features intended to enable lifetime management solutions such as coronary access.
The Evolut™ PRO+ TAVI system features the lowest delivery profile for 23–29 mm valves and advanced sealing with an external tissue wrap on all valve sizes.
† In pooled analysis of intermediate and high-risk patients. Devices used: CoreValve™ 88.5%/Evolut™ R 11.5%.
‡ Structural valve deterioration (SVD) was defined as an increase in mean gradient ≥ 10 mmHg with a mean gradient ≥ 20 mmHg at last echo OR new onset/increase of central AR of ≥ moderate in severity.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
